Castration-naive metastatic prostate cancer: reshaping old paradigms.

about

Castration-naive metastatic prostate cancer: reshaping old paradigms.

Item

http://www.wikidata.org/entity/Q50270201

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@en

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@nl

type

Item

label

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@en

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@nl

prefLabel

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@en

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@nl

P1476

Castration-naive metastatic prostate cancer: reshaping old paradigms.

@en

P2093

Elena Verzoni

http://www.w3.org/2001/XMLSchema#string

Paolo Grassi

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

P304

879-881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14737140.2017.1374178

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Procopio

Giovanni Fucà

Raffaele Ratta

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28854837

http://www.w3.org/2001/XMLSchema#string